Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control ...

Capricor Therapeutics (CAPR) announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. Given this risk, we thought we'd take a look at whether Capricor Therapeutics (NASDAQ:CAPR) ...

Capricor Therapeutics finds itself navigating turbulent waters as a federal securities class action lawsuit casts uncertainty over the company's future. The legal investigation, made public on October ...

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Medivir AB, with a price target of SEK54.00. The company’s shares closed yesterday at SEK0.51. Take ...

Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Capricor Therapeutics, Inc. before investing. In this article, we go over a few ...